Aktis Oncology, Inc.
- AKTS ยท Nasdaq
- Pharmaceutical Preparations
- Boston, MA
- 79 employees
- CIK 0002035832
Updated from SEC filings through
Top things to know
Executives
-
Matthew Roden, PhD President and Chief Executive Officer 10-K, 2026-03-30 -
Kyle D. Kuvalanka Chief Financial Officer 10-K, 2026-03-30 -
Akos Czibere Chief Medical Officer 4, 2026-09-24 -
Shulamit Ron-Bigger Chief Operating Officer 4, 2026-07-10 -
Paul L. Feldman, PhD Chief Scientific Officer 10-K, 2026-03-30 -
Tyler Benedum, PhD Chief Technical Officer 10-K, 2026-03-30
Aktis Oncology, Inc. is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Boston, MA. It trades as AKTS on Nasdaq. It reported about 79 employees. Matthew Roden, PhD is President and Chief Executive Officer.
Five-year financials
We have no annual financials for this company yet.
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Matthew Roden, PhD | President and Chief Executive Officer | 10-K, 2026-03-30 |
| Kyle D. Kuvalanka Chief Financial Officer, Aktis Oncology | Chief Financial Officer | 10-K, 2026-03-30 |
| Akos Czibere | Chief Medical Officer | 4, 2026-09-24 |
| Shulamit Ron-Bigger Chief Operating Officer at Aktis Oncology | Chief Operating Officer | 4, 2026-07-10 |
| Paul L. Feldman, PhD | Chief Scientific Officer | 10-K, 2026-03-30 |
| Tyler Benedum, PhD | Chief Technical Officer | 10-K, 2026-03-30 |
| Helen S. Kim, MBA | Director | 10-K, 2026-03-30 |
| Ken Herrmann, MD | Director | 10-K, 2026-03-30 |
What Aktis Oncology, Inc. does
We are a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The field of targeted radiopharmaceuticals is currently led by two marketed products that illustrated transformative survival outcomes and quality of life benefits can be conferred by delivering radioisotopes to solid tumors.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Reportable segments | 1 (period ending June 30, 2026) | 10-Q, August 13, 2026 |
|---|
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| September 23, 2026 | Akos Czibere Chief Medical Officer | Sale | 12,500 | $259K | Form 4, September 24, 2026 |
| July 20, 2026 | Ken Herrmann Director | Sale | 4,856 | $119K | Form 4, July 21, 2026 |
| July 17, 2026 | Ken Herrmann Director | Sale | 3,065 | $77K | Form 4, July 20, 2026 |
| July 8, 2026 | Shulamit Ron-Bigger Chief Operating Officer | Sale | 50,000 | $1.4M | Form 4, July 10, 2026 |
| July 8, 2026 | Akos Czibere Chief Medical Officer | Sale | 50,000 | $1.4M | Form 4, July 10, 2026 |
| January 12, 2026 | Todd Foley Director | Buy | 232,870 | $4.2M | Form 4, January 14, 2026 |
| January 12, 2026 | Helen Susan Kim Director | Buy | 835,000 | $15.0M | Form 4, January 12, 2026 |
| January 12, 2026 | Oleg Nodelman Director | Buy | 2,222,222 | $40.0M | Form 4, January 12, 2026 |
Recent 8-K events
- 8-K filed 2026-08-13
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-05-11
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-04-16
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-03-30
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-01-12
- Item 5.03 Amendments to articles or bylaws; change in fiscal year
Frequently asked questions about Aktis Oncology, Inc.
- What does Aktis Oncology, Inc. do?
- In its own words, from Item 1 of its 10-K: "We are a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The field of targeted radiopharmaceuticals is currently led by two marketed products that illustrated transformative survival outcomes and quality of life benefits can be conferred by delivering radioisotopes to solid tumors."
- How many employees does Aktis Oncology, Inc. have?
- About 79 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Aktis Oncology, Inc.?
- Matthew Roden, PhD, President and Chief Executive Officer, as named in a 10-K filed March 30, 2026.
- Who is the CFO of Aktis Oncology, Inc.?
- Kyle D. Kuvalanka, Chief Financial Officer, as named in a 10-K filed March 30, 2026.
- Where is Aktis Oncology, Inc. headquartered?
- Boston, MA.
- What is Aktis Oncology, Inc.'s stock ticker?
- AKTS on Nasdaq.
- What industry is Aktis Oncology, Inc. in?
- Pharmaceutical Preparations, SIC code 2834.
- What is Aktis Oncology, Inc.'s website?
- aktisoncology.com.
- When does Aktis Oncology, Inc. report earnings next?
- November 12, 2026. Source: pg_future_events.
- Is Aktis Oncology, Inc. a public company?
- Yes. Aktis Oncology, Inc. files with the SEC under CIK 0002035832 and trades as AKTS.
- How many business segments does Aktis Oncology, Inc. report?
- 1 reportable segment for the period ending June 30, 2026, from its 10-Q filed August 13, 2026.
- Have Aktis Oncology, Inc. insiders traded stock recently?
- Since January 12, 2026, officers and directors reported 5 open-market sales worth about $3.2M and 4 purchases worth about $99.2M on Forms 4 and 5. The most recent: Akos Czibere (Chief Medical Officer) sold 12,500 shares on September 23, 2026.